免疫效应细胞相关肠炎的组织学谱系与 T 细胞克隆性特征 Characterization of Histologic Spectrum and T-Cell Clonality in Immune Effector Cell-Associated Enteritis. PubMed 2026/09/19 发表Hum PatholQ2 · IF 3(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T弥漫大B细胞淋巴瘤多发性骨髓瘤淋巴瘤
下一代基于抗体的癌症治疗:抗体-药物偶联物和双特异性抗体在血液系统恶性肿瘤和实体瘤中的应用 Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors PubMed 2026/09/09 发表J Hematol OncolQ1 · IF 47.8(JCR 2025) 靶点:CD19靶点:CD20靶点:BCMA技术:CAR-T技术:双特异性抗体急性淋巴细胞白血病多发性骨髓瘤B细胞淋巴瘤
AML/MDS 细胞治疗的最新进展 Recent advances in cell therapy for AML/MDS. PubMed 2026/09/04 发表Int J HematolQ3 · IF 1.9(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T技术:CAR-NK技术:NK 细胞骨髓增生异常综合征急性髓系白血病多发性骨髓瘤
辐照 CD19 嵌合抗原受体 YTS 细胞保留抗肿瘤活性并可作为自体 CAR-T 疗法的可规模化替代方案 Irradiated CD19 chimeric antigen receptor YTS cells retain antitumor activity and offer a scalable alternative to autologous CAR-T therapy. PubMed 2026/08/13 发表HaematologicaQ1 · IF 8.2(JCR 2025) 靶点:CD19技术:CAR-T技术:NK 细胞多发性骨髓瘤实体瘤淋巴瘤
CD19 与 BCMA 靶向 CAR-T 细胞治疗中输注前宿主骨髓易感性:克隆性造血、血液毒性与治疗相关髓系肿瘤 Pre-Infusion Host-Marrow Vulnerability in CD19- and BCMA-Directed CAR T-Cell Therapy: Clonal Hematopoiesis, Hematotoxicity, and Therapy-Related Myeloi PubMed 2026/07/18 发表Cancer Manag ResQ3 · IF 2.6(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T多发性骨髓瘤淋巴瘤地区:中国
超越传统嵌合抗原受体:拓展 CAR-T 细胞疗法中的可靶向抗原版图 Beyond Conventional Chimeric Antigen Receptors: Expanding the Targetable Antigen Landscape in Chimeric Antigen Receptor-T Cell Therapy. PubMed 2026/07/08 发表Transplant Cell TherQ1 · IF 4.7(JCR 2025) 靶点:CD19技术:CAR-T多发性骨髓瘤实体瘤地区:亚太其他地区:其他
Idecabtagene Vicleucel 后 100 天内的感染及其对复发/难治性多发性骨髓瘤生存的影响:一项 CIBMTR 分析 Infections Within 100 Days of Idecabtagene Vicleucel and Impact on Survival for Relapsed/Refractory Multiple Myeloma: A CIBMTR Analysis. PubMed 2026/06/27 发表Transplant Cell TherQ1 · IF 4.7(JCR 2025) 靶点:CD19靶点:BCMA技术:CAR-T多发性骨髓瘤地区:亚太其他地区:美国
BCMA/CD19 双靶向 CAR-T 细胞疗法用于新诊断多发性骨髓瘤老年患者:一项 1 期研究 BCMA/CD19 dual-targeting CAR T-cell therapy in older patients with newly diagnosed multiple myeloma: a phase 1 study. PubMed 2026/06/23 发表Blood AdvQ1 · IF 7.7(JCR 2025) 人群:成人靶点:CD19靶点:BCMA技术:CAR-T多发性骨髓瘤地区:中国
CAR-T 细胞治疗前基于苯达莫司汀的淋巴细胞清除:一项系统综述 Bendamustine-based lymphodepletion prior to CAR T-cell therapy: a systematic review. PubMed 2026/06/22 发表Bone Marrow TransplantQ1 · IF 5.1(JCR 2025) 靶点:CD19靶点:CD30靶点:BCMA技术:CAR-T技术:造血干细胞非霍奇金淋巴瘤霍奇金淋巴瘤多发性骨髓瘤
通过确定的逻辑门 CAR 策略克服靶向 CD86 的 CAR-T 细胞的自相残杀 Overcoming fratricide of CD86 targeting CAR-T cells by defined logic-gate CAR strategy. PubMed 2026/06/18 发表Exp Hematol OncolQ1 · IF 17.5(JCR 2025) 靶点:CD19技术:CAR-T多发性骨髓瘤急性髓系白血病慢性髓系白血病地区:欧洲